Rare Hematology News

Advertisement

Spotlight On

Diamond-Blackfan anemia

Diamond-Blackfan anemia is an inherited blood disorder that affects the ability of the bone marrow to produce red blood cells. It's characterized by pure red cell aplasia, meaning the bone marrow is unable to generate red blood cells, while other blood cell types are usually normal

Prevalence

600–1,000

US Estimated

800–1,200

Europe Estimated

Age of Onset

Infancy

ICD-10

D61.0

Inheritance Pattern

Autosomal dominant

Autosomal recessive

Mitochondrial/Multigenic

X-linked dominant

X-linked recessive

5 Facts you should know

FACT

1

Craniofacial anomalies, thumb malformations, and short stature are common physical features, often prompting genetic evaluation in infants with unexplained anemia

FACT

2

DBA typically presents within the first year of life as macrocytic anemia with reticulocytopenia and normal marrow cellularity but absent erythroid precursors

FACT

3

More than 50% of cases are linked to mutations in ribosomal protein genes (e.g., RPS19, RPL5), highlighting DBA as a ribosomopathy with defective ribosome biogenesis

FACT

4

Patients are at elevated risk for malignancies, including acute myeloid leukemia (AML), osteogenic sarcoma, and myelodysplastic syndromes, requiring long-term monitoring

FACT

5

Management includes corticosteroid therapy, chronic red blood cell transfusions, iron chelation, and hematopoietic stem cell transplantation, which offers curative potential in select cases

Diamond-Blackfan Anemia is also known as...

Diamond-Blackfan Anemia is also known as:

  • DBA
  • Anemia Diamond Blackfan type
  • Blackfan Diamond syndrome

What’s your Rare IQ?

What type of anemia is most characteristic of Diamond-Blackfan Anemia?
 

Common signs & symptoms

Macrocytic anemia

low red blood cell counts

Congenital abnormalities

e.g., craniofacial, limb, cardiac defects

Failure to thrive

Pallor, fatigue, tachycardia

Increased risk of malignancies

especially MDS and leukemia

Elevated erythrocyte adenosine deaminase (eADA) levels

Current treatments

Corticosteroids

initial treatment to stimulate red blood cell production

Chronic red blood cell transfusions

the only curative therapy

Iron chelation therapy

to address iron overload

Hematopoietic stem cell transplant (HSCT)

potential cure in severe/transfusion-dependent cases

Surveillance for malignancy and organ complications